Harmar invests in Mabtech

Mabtech is a Swedish biotech company developing immunoassays for life science research. Since 1986, Mabtech’s mission has been to aid research by providing the global scientific community with innovative tools. To that end, the company generates and produces a wide range of monoclonal antibodies, kits, peptide pools, and instruments for in vitro applications.

Harmar is co-investing alongside EQT and Harry Klagsbrun will join the Board of Directors. Together they will support Mabtech as it expands its product portfolio and reach, especially in the US.

For more information, visit https://www.mabtech.com/